BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30355696)

  • 1. Functional Mapping of Regions Involved in the Negative Imprinting of Virion Particle Infectivity and in Target Cell Protection by Interferon-Induced Transmembrane Protein 3 against HIV-1.
    Appourchaux R; Delpeuch M; Zhong L; Burlaud-Gaillard J; Tartour K; Savidis G; Brass A; Etienne L; Roingeard P; Cimarelli A
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Heterogeneity of Mammalian IFITM Proteins against HIV-1.
    Marziali F; Delpeuch M; Kumar A; Appourchaux R; Dufloo J; Tartour K; Etienne L; Cimarelli A
    J Virol; 2021 Aug; 95(18):e0043921. PubMed ID: 34160255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity.
    Wang Y; Pan Q; Ding S; Wang Z; Yu J; Finzi A; Liu SL; Liang C
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28100616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.
    Tartour K; Nguyen XN; Appourchaux R; Assil S; Barateau V; Bloyet LM; Burlaud Gaillard J; Confort MP; Escudero-Perez B; Gruffat H; Hong SS; Moroso M; Reynard O; Reynard S; Decembre E; Ftaich N; Rossi A; Wu N; Arnaud F; Baize S; Dreux M; Gerlier D; Paranhos-Baccala G; Volchkov V; Roingeard P; Cimarelli A
    PLoS Pathog; 2017 Sep; 13(9):e1006610. PubMed ID: 28957419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-Induced Transmembrane Protein 3 Is a Virus-Associated Protein Which Suppresses Porcine Reproductive and Respiratory Syndrome Virus Replication by Blocking Viral Membrane Fusion.
    Zhang A; Duan H; Zhao H; Liao H; Du Y; Li L; Jiang D; Wan B; Wu Y; Ji P; Zhou EM; Zhang G
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
    Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
    mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity.
    Tartour K; Appourchaux R; Gaillard J; Nguyen XN; Durand S; Turpin J; Beaumont E; Roch E; Berger G; Mahieux R; Brand D; Roingeard P; Cimarelli A
    Retrovirology; 2014 Nov; 11():103. PubMed ID: 25422070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duck Interferon-Inducible Transmembrane Protein 3 Mediates Restriction of Influenza Viruses.
    Blyth GA; Chan WF; Webster RG; Magor KE
    J Virol; 2016 Jan; 90(1):103-16. PubMed ID: 26468537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment.
    Xie M; Xuan B; Shan J; Pan D; Sun Y; Shan Z; Zhang J; Yu D; Li B; Qian Z
    J Virol; 2015 Mar; 89(6):3049-61. PubMed ID: 25552713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression.
    Wang Q; Su L
    mBio; 2019 Aug; 10(4):. PubMed ID: 31431548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry.
    Anafu AA; Bowen CH; Chin CR; Brass AL; Holm GH
    J Biol Chem; 2013 Jun; 288(24):17261-71. PubMed ID: 23649619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFITM1 and IFITM3 Proteins Inhibit the Infectivity of Progeny HIV-1 without Disrupting Envelope Glycoprotein Clusters.
    Verma S; Chen YC; Marin M; Gillespie SE; Melikyan GB
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion.
    Desai TM; Marin M; Chin CR; Savidis G; Brass AL; Melikyan GB
    PLoS Pathog; 2014 Apr; 10(4):e1004048. PubMed ID: 24699674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV.
    Wilkins J; Zheng YM; Yu J; Liang C; Liu SL
    PLoS One; 2016; 11(6):e0156739. PubMed ID: 27257969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry.
    Amini-Bavil-Olyaee S; Choi YJ; Lee JH; Shi M; Huang IC; Farzan M; Jung JU
    Cell Host Microbe; 2013 Apr; 13(4):452-64. PubMed ID: 23601107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphavirus Restriction by IFITM Proteins.
    Weston S; Czieso S; White IJ; Smith SE; Wash RS; Diaz-Soria C; Kellam P; Marsh M
    Traffic; 2016 Sep; 17(9):997-1013. PubMed ID: 27219333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.
    Yu J; Li M; Wilkins J; Ding S; Swartz TH; Esposito AM; Zheng YM; Freed EO; Liang C; Chen BK; Liu SL
    Cell Rep; 2015 Oct; 13(1):145-156. PubMed ID: 26387945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.
    Zhao X; Sehgal M; Hou Z; Cheng J; Shu S; Wu S; Guo F; Le Marchand SJ; Lin H; Chang J; Guo JT
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity.
    Compton AA; Roy N; Porrot F; Billet A; Casartelli N; Yount JS; Liang C; Schwartz O
    EMBO Rep; 2016 Nov; 17(11):1657-1671. PubMed ID: 27601221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes.
    Suddala KC; Lee CC; Meraner P; Marin M; Markosyan RM; Desai TM; Cohen FS; Brass AL; Melikyan GB
    PLoS Pathog; 2019 Jan; 15(1):e1007532. PubMed ID: 30640957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.